Key result
Elevated BNP levels (>40.5 pg/mL) 3 months after atrial fibrillation ablation were associated with increased arrhythmia recurrence compared to non-elevated levels (34.4% vs. 10.9%; HR 2.43, p=0.014).
Why the study?
The role of BNP levels as a predictor of arrhythmia recurrence after AF ablation remains unclear.
Do elevated BNP levels 3 months after atrial fibrillation ablation predict arrhythmia recurrence in patients undergoing their first ablation?
Cohort (n=234)
Do elevated BNP levels 3 months after atrial fibrillation ablation predict arrhythmia recurrence in patients undergoing their first ablation?
Hazard Ratio: 2.43
Absolute Event Rate: 34.4% vs 10.9%
p-value: p=0.014
Elevated BNP levels at 3 months, but not at baseline, serve as a significant prognostic factor for arrhythmia recurrence after a first atrial fibrillation ablation.
Elevated post-ablation BNP may aid AF recurrence risk stratification; hypothesis-generating and requires prospective validation before guiding practice.
The role of B-type natriuretic peptide (BNP) levels as a predictor of arrhythmia recurrence (AR) after atrial fibrillation (AF) ablation remains unclear. In this study, we investigated the association of BNP levels before and 3 months after ablation with the risk of AR. A total of 234 patients undergoing their first session of AF ablation were included (68% male, mean age of 69 years). The cut-off value for discriminating AR was determined based on the maximum value of the area under the receiver operating characteristic (ROC) curve. The impact of BNP levels on AR was evaluated using Cox regression analysis. ROC curve analysis showed that the area under the curve for BNP at 3 months after the procedure was larger (0.714) compared to BNP levels before ablation (0.593). Elevated levels of BNP 3 months after the procedure (>40.5 pg/mL, n = 96) was associated with a higher risk of AR compared to those without elevated levels (34.4% vs. 10.9%, p < 0.01). Multivariate Cox regression analysis revealed that elevated BNP levels were associated with an increased risk of AR (hazard ratio 2.43; p = 0.014). Elevated BNP levels 3 months after AF ablation were a significant prognostic factor in AR, while baseline BNP levels were not.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2021) conducted a cohort in Atrial Fibrillation (n=234). Elevated BNP levels 3 months after ablation (>40.5 pg/mL) vs. BNP levels ≤40.5 pg/mL was evaluated on Arrhythmia recurrence (HR 2.43, p=0.014). Elevated BNP levels (>40.5 pg/mL) 3 months after atrial fibrillation ablation were associated with increased arrhythmia recurrence compared to non-elevated levels (34.4% vs. 10.9%; HR 2.43, p=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: